These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 27847153)

  • 1. The potential application and challenge of powerful CRISPR/Cas9 system in cardiovascular research.
    Li Y; Song YH; Liu B; Yu XY
    Int J Cardiol; 2017 Jan; 227():191-193. PubMed ID: 27847153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
    Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
    Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress of application and off-target effects of CRISPR/Cas9.
    Zheng W; Gu F
    Yi Chuan; 2015 Oct; 37(10):1003-10. PubMed ID: 26496752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene targeting technologies in rats: zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats.
    Mashimo T
    Dev Growth Differ; 2014 Jan; 56(1):46-52. PubMed ID: 24372523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome editing for human gene therapy.
    Meissner TB; Mandal PK; Ferreira LM; Rossi DJ; Cowan CA
    Methods Enzymol; 2014; 546():273-95. PubMed ID: 25398345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multiplexed CRISPR targeting platforms.
    Cao J; Xiao Q; Yan Q
    Drug Discov Today Technol; 2018 Aug; 28():53-61. PubMed ID: 30205881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review.
    Musunuru K
    JAMA Cardiol; 2017 Aug; 2(8):914-919. PubMed ID: 28614576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plant genome engineering in full bloom.
    Lozano-Juste J; Cutler SR
    Trends Plant Sci; 2014 May; 19(5):284-7. PubMed ID: 24674878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9: at the cutting edge of hepatology.
    Pankowicz FP; Jarrett KE; Lagor WR; Bissig KD
    Gut; 2017 Jul; 66(7):1329-1340. PubMed ID: 28487442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
    Duroux-Richard I; Giovannangeli C; Apparailly F
    Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
    [No Abstract]   [Full Text] [Related]  

  • 18. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.